Back to News
Market Impact: 0.2
Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
Source: PR Newswire
Healthcare & BiotechProduct Launches
The global Phase III DEEp SEA trial of investigational bexicaserin has completed randomization in children and adults with Dravet syndrome. The milestone advances the broader DEEp clinical-development program, although the article provides no efficacy, safety, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Backbone of a beast – charting Nvidia's rise to networking titan
- Anthropic's IPO push includes a big bet on life sciences
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat